Gradient Investments LLC raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 212.7% during the second quarter, Holdings Channel reports. The firm owned 24,090 shares of the company’s stock after buying an additional 16,386 shares during the period. Gradient Investments LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $800,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Cribstone Capital Management LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 3.3% in the first quarter. Cribstone Capital Management LLC now owns 3,141 shares of the company’s stock worth $101,000 after buying an additional 100 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the last quarter. FNY Managed Accounts LLC purchased a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth $123,000. Sterling Investment Advisors Ltd. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the last quarter. Finally, Financial Architects Inc raised its position in shares of Teva Pharmaceutical Industries Limited by 2.3% in the first quarter. Financial Architects Inc now owns 4,443 shares of the company’s stock worth $143,000 after buying an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 56.26% of the company’s stock.
Teva Pharmaceutical Industries Limited (TEVA) traded down 0.22% during trading on Friday, reaching $32.36. The company’s stock had a trading volume of 1,289,905 shares. Teva Pharmaceutical Industries Limited has a 1-year low of $27.59 and a 1-year high of $55.79. The company has a market capitalization of $32.88 billion, a P/E ratio of 414.87 and a beta of 0.47. The company’s 50-day moving average is $31.34 and its 200-day moving average is $32.48.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, May 11th. The company reported $1.06 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.06. The company had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The firm’s revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.20 earnings per share. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.75 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, June 22nd. Shareholders of record on Monday, June 5th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, June 1st. This represents a $1.36 annualized dividend and a yield of 4.19%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently 5,802.90%.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://stocknewstimes.com/2017/07/21/teva-pharmaceutical-industries-limited-nyseteva-position-increased-by-gradient-investments-llc.html.
TEVA has been the topic of a number of research reports. CIBC restated a “buy” rating and issued a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Friday, April 7th. Oppenheimer Holdings, Inc. set a $43.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a report on Thursday, April 6th. Vetr lowered Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $36.17 price objective on the stock. in a report on Thursday, April 6th. Citigroup Inc. decreased their price objective on Teva Pharmaceutical Industries Limited from $47.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, April 25th. Finally, Deutsche Bank AG decreased their price objective on Teva Pharmaceutical Industries Limited from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, May 12th. Sixteen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Teva Pharmaceutical Industries Limited currently has an average rating of “Hold” and a consensus price target of $42.78.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
